{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T17:26:37Z","timestamp":1769016397838,"version":"3.49.0"},"reference-count":17,"publisher":"Japanese Society of Internal Medicine","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2024,3,1]]},"DOI":"10.2169\/internalmedicine.2182-23","type":"journal-article","created":{"date-parts":[[2023,7,18]],"date-time":"2023-07-18T22:11:26Z","timestamp":1689718286000},"page":"729-732","source":"Crossref","is-referenced-by-count":2,"title":["Clinical Features of Clonal Cytogenetic Abnormalities in Philadelphia-negative Cells Developed During Tyrosine Kinase Inhibitor Treatment"],"prefix":"10.2169","volume":"63","author":[{"given":"Kana","family":"Oiwa","sequence":"first","affiliation":[{"name":"Division of Hematology and Oncology, University of Fukui, Japan"},{"name":"Division of Internal Medicine, Osu Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, University of Fukui, Japan"},{"name":"Department of Hematology, Matsunami General Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kei","family":"Fujita","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, University of Fukui, Japan"},{"name":"Department of Hematology, Matsunami General Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takanori","family":"Ueda","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, University of Fukui, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Yamauchi","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, University of Fukui, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. New Engl J Med 348: 994-1004, 2003.","DOI":"10.1056\/NEJMoa022457"},{"key":"2","doi-asserted-by":"publisher","unstructured":"2. Ottmann OG, Druker BJ, Sawyers CL, et al. A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood 100: 1965-1971, 2002.","DOI":"10.1182\/blood-2001-12-0181"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Blay JY, Hindi N, Bollard J, et al. SELNET clinical practice guidelines for soft tissue sarcoma and GIST. Cancer Treat Rev 102: 102312, 2022.","DOI":"10.1016\/j.ctrv.2023.102523"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Nakamae H, Fujisawa S, Ogura M, et al. Dasatinib versus imatinib in Japanese patients with newly diagnosed chronic phase chronic myeloid leukemia: a subanalysis of the DASISION 5-year final report. Int J Hematol 105: 792-804, 2017.","DOI":"10.1007\/s12185-017-2208-2"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Nakamae H, Fukuda T, Nakaseko C, et al. Nilotinib vs. imatinib in Japanese patients with newly diagnosed chronic myeloid leukemia in chronic phase: long-term follow-up of the Japanese subgroup of the randomized ENESTnd trial. Int J Hematol 107: 327-336, 2018.","DOI":"10.1007\/s12185-017-2353-7"},{"key":"6","doi-asserted-by":"publisher","unstructured":"6. Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 122: 872-884, 2013.","DOI":"10.1182\/blood-2013-05-501569"},{"key":"7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cancergen.2017.04.066","volume":"216","author":"EM Wasilewska","year":"2017","unstructured":"7. Wasilewska EM, Panasiuk B, Gniot M, et al. Clonal chromosomal aberrations in Philadelphia negative cells such as monosomy 7 and trisomy 8 may persist for years with no impact on the long term outcome in patients with chronic myeloid leukemia. Cancer Genetics 216: 1-9, 2017.","journal-title":"Cancer Genetics","ISSN":"https:\/\/id.crossref.org\/issn\/2210-7762","issn-type":"print"},{"key":"8","doi-asserted-by":"publisher","unstructured":"8. Issa GC, Kantarjian HM, Gonzalez GN, et al. Clonal chromosomal abnormalities appearing in Philadelphia chromosome-negative metaphases during CML treatment. Blood 130: 2084-2091, 2017.","DOI":"10.1182\/blood-2017-07-792143"},{"key":"9","doi-asserted-by":"publisher","unstructured":"9. Kovitz C, Kantarjian H, Garcia-Manero G, Abruzzo LV, Cortes J. Myelodysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukemia. Blood 108: 2811-2813, 2006.","DOI":"10.1182\/blood-2006-04-017400"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Mallik N, Chopra A, Jha A, Gogia A, Kumar R. Development of myelodysplastic syndrome in a patient with chronic myelogenous leukemia treated with imatinib. Leuk Lymphoma 56: 1143-1144, 2015.","DOI":"10.3109\/10428194.2014.941831"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Pitini V, Arrigo C, Sauta MG, Altavilla G. Myelodysplastic syndrome appearing during imatinib mesylate therapy in a patient with GIST. Leuk Res 33: e143-e144, 2009.","DOI":"10.1016\/j.leukres.2009.04.012"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Chen X, Zheng J, Liang K, et al. Characterisation of clonal Philadelphia-negative cytogenetic abnormalities in a large cohort of chronic myeloid leukaemia. Int Med J 48: 439-444, 2018.","DOI":"10.1111\/imj.13527"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Deininger MW, Cortes J, Paquette R, et al. The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome-negative cells. Cancer 110: 1509-1519, 2007.","DOI":"10.1002\/cncr.22936"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Sasaki K, Kantarjian HM, O'Brien S, et al. Incidence of second malignancies in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors. Int J Hematol 109: 545-552, 2019.","DOI":"10.1007\/s12185-019-02620-2"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Karimata K, Masuko M, Ushiki T, et al. Myelodysplastic syndrome with Ph negative monosomy 7 chromosome following transient bone marrow dysplasia during imatinib treatment for chronic myeloid leukemia. Int Med (Tokyo, Japan) 50: 481-485, 2011.","DOI":"10.2169\/internalmedicine.50.4481"},{"key":"16","doi-asserted-by":"publisher","unstructured":"16. Wang JY. Regulation of cell death by the Abl tyrosine kinase. Oncogene 19: 5643-5650, 2000.","DOI":"10.1038\/sj.onc.1203878"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Wang X, Zeng L, Wang J, et al. A positive role for c-Abl in Atm and Atr activation in DNA damage response. Cell Death Differ 18: 5-15, 2011.","DOI":"10.1038\/cdd.2010.106"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/63\/5\/63_2182-23\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T04:31:17Z","timestamp":1715574677000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/63\/5\/63_2182-23\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,1]]},"references-count":17,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.2182-23","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,1]]},"article-number":"2182-23"}}